EffRx Pharmaceuticals Announces the Release of Binosto® Data in Two Publications

FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced the publication of new scientific data on its Binosto® (buffered soluble alendronate). The data appeared in two major medical journals.1,2

The findings from the study “A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post‑menopausal women with osteoporosis” demonstrate that Binosto® can provide greater persistence and improved tolerability compared to alendronate tablets, allowing it to be a viable alternative option in the management of osteoporosis.

The article “Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy” provides an economic analysis which indicates that Binosto® may represent a cost-effective strategy compared with relevant alternative treatments for the treatment of postmenopausal women with osteoporosis in Italy aged 60 years and over.

Both publications can be found at: https://doi.org/10.1007/s40520-020-01777-9 and https://doi.org/10.1007/s00198-020-05802-5

  1. Giusti, A., Bianchi, G., Barone, A. et al. A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis. Aging Clin Exp Res (2021). https://doi.org/10.1007/s40520-020-01777-9
  2. Hiligsmann, M., Maggi, S., Veronese, N. et al. Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporos Int (2021). https://doi.org/10.1007/s00198-020-05802-5

 

About EffRx Pharmaceuticals

EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.

EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from the FDA for a pipeline asset.

EffRx’s go-to-market competence is proven by the development, launch and lucrative expansion of Binosto® in a highly competitive European market. Our lead commercialized product, Binosto® for the treatment of osteoporosis, is marketed in the US as well as selected European and Asian countries.

Disclaimer: Information for investors. Please always refer to the official Prescribing Information of Binosto® containing the approved indications, contraindications, safety information and warnings in your country.